FR0000120578 - Common Stock
We assign a fundamental rating of 3 out of 10 to SAN. SAN was compared to 20 industry peers in the Pharmaceuticals industry. SAN has a bad profitability rating. Also its financial health evaluation is rather negative. SAN has a correct valuation and a medium growth rate.
Note: SAN has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profit Margin (16.43%) VS Industry: 66% outperformed.
Price/Earnings (10.92) VS Industry: 58% outperformed.
Enterprise Value/ EBITDA (10.92) VS Industry: 33% outperformed.
Dividend Yield (3.85%) VS Industry: 77% outperformed.
EPA:SAN (11/30/2022, 7:00:00 PM)-1.71 (-1.94%)
|GICS Sector||Health Care|
|GICS IndustryGroup||Pharmaceuticals, Biotechnology & Life Sciences|
|Earnings (Last)||N/A N/A||Earnings (Next)||N/A N/A|
|Ins Owners||N/A||Inst Owners||N/A|
|PEG (NY)||0.45||PEG (5Y)||3.81|
|Dividend Yield||3.85%||Dividend Growth||2.57%|
|EPS 1Y||23.94%||EPS 3Y||6.19%|
|EPS 5Y||2.87%||EPS growth Q2Q||31.65%|
|EPS Next Y||24.49%||EPS Next 2Y||13.9%|
|EPS Next 3Y||11.48%||EPS Next 5Y||8.83%|
|Revenue growth 1Y||13.92%||Revenue growth 3Y||3.17%|
|Revenue growth 5Y||2.46%||Revenue growth Q2Q||21.32%|
|Revenue Next Year||13.01%||Revenue Next 2Y||8.73%|
|Revenue Next 3Y||7.33%||Revenue Next 5Y||4.7%|
|Current Ratio||N/A||Quick Ratio||N/A|
Find stocks with similar Fundamental rating on the EuroNext
Find the competitors with the best fundamentals on the EuroNext
Find the competitors with the best valuation on the EuroNext
Find the competitors with the best dividend on the EuroNext